Tarsus Pharmaceuticals Q3 product sales jump 64%, beating estimates
TARS•Tarsus Pharmaceuticals’ third-quarter product sales rose 64% year over year to $194.57 million, topping the $186.60 million analyst consensus. The company reported a net loss of $668.33 million, reflecting acquisition-related research and development expenses.
1. Sales and results
Tarsus Pharmaceuticals reported third-quarter product sales of $194.57 million, up 64% year over year and above the $186.60 million consensus estimate. Higher sales volume of XDEMVY, broader prescribing by eye care professionals and marketing campaigns contributed to growth. The company posted a net loss of $668.33 million, with operating expenses of $856.66 million; it said the loss reflected acquisition-related research and development expenses.
2. Pipeline and appointment
Tarsus expects topline data from its TP-04 and TP-05 trials in the first half of 2027. It plans to begin a Phase 3 IRX-101 study in the first half of 2027, with topline results expected in 2028. Enrollment is continuing in the Phase 3 Northstar trial for gildeuretinol, with topline results expected in 2029. The company appointed Neera Clase as chief commercial officer.
